Monday, August 31, 2026

NIO Stock Correcting 5% Down On Wednesday At 11:05 EST

ViaNews Editorial Team

November 18, 2020

NIO Stock Correcting 5% Down On Wednesday At 11:05 EST
Even though NIO Limited has been somewhat immune to the crisis, shares dropping 5.32% to $44.11 at 11:05 EST, on Wednesday. The New York Stock Exchange rose 0.33% to $13994.9, on what seems at the moment an all-around rough trading session for the stock market. This was the New York Stock Exchange two consecutive sessions of gains. NIO Limited last close was $46.59, under its 52-week high of $54.2. NIO Limited's sales growth is 98.6% for the ongoing quarter and 262.3% for the next. The company's growth estimates for the current quarter and the next are 61.5% and 47.8%, respectively. NIO Limited's stock is valued at $44.11 at 16:05 EST, way below its 52 Week High of $54.2 and way higher than its 52 Week Low of $1.77. NIO Limited's value is way higher than its 50 day moving average of $30.69. NIO Limited's worth is way above its 200 day moving average of $16.26.
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com